Progestins and breast cancer

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 5, 2003, Pages 1123-1131

  Eden, John ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast cancer; Estrogen; Estrogen replacement therapy; Hormone replacement therapy; Progestins

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; PROGESTERONE; PROMEGESTONE;

BREAST CANCER; CANCER INHIBITION; CANCER RISK; CLINICAL TRIAL; ESTROGEN THERAPY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0038396147     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.201     Document Type: Review

References (135)

1. American Cancer Society. Cancer facts and figures - 1998. Atlanta (GA): American Cancer Society; 1998.
2. Schneider HP. HRT and cancer risk: separating fact from fiction. Maturitas 1999;33(1 Suppl):S65-72.
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
4. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
5. Johnson SR. Menopause and hormone replacement therapy. Med Clin North Am 1998;82:297-320.
6. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
7. Notelovitz M. Estrogen therapy and osteoporosis: principles and practice. Am J Med Sci 1997;313:2-12.
8. Brunelli MP, Einhorn TA. Medical management of osteoporosis: fracture prevention. Clin Orthop 1998;348:15-21.
9. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.
10. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med 2000;160:2265-72.
11. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-7.
12. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-21.
13. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
14. Schairer C, Lubin J, Triosi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
15. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
16. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502-19.
17. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
18. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, et al. Mice lacking progesterone receptor exhibit pleiontropic reproductive abnormalities. Genes Dev 1995;9:2266-78.
19. Humphreys RC, Lydon JP, O'Malley BW, Rosen JM. Use of PRKO mice to study the role of progesterone in mammary gland development. J Mammary Gland Biol Neoplasia 1997;2:343-54.
20. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621-30.
21. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997;11:179-86.
22. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997;94:7239-44.
23. Lange CA, Richer JK, Horwitz KB. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999;13:829-36.
24. Chang K-J, Lee TTY, Linares-Cruz G, Fournier S, De Lignieres B. Influences of percutaneous administration of estradiol and progesterone of human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785-91.
25. Foidart J-M, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, et al. Estradiol and progesterone regulate the proliferation of human breast endothelial cells. Fertil Steril 1998;69:963-9.
26. Edery M, McGrath M, Larson L, Nandi S. Correlation between in vitro growth and regulation of estrogen and progesterone receptors in rat mammary epithelia cells. Endocrinology 1984;115:1691-7.
27. McGrath M, Palmer S, Nandi S. Differential response of normal rat mammary epithelial cells to mammogenic hormones and EGF. J Cell Physiol 1985;125:182-91.
28. Malet C, Spritzer P, Guillaumin D, Kuttenn F. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial (HBE) cells in culture. J Steroid Biochem Mol Biol 2000;73:171-81.
29. Ciark JH, Peck EJ Jr. Female sex steroids: receptors and function. New York: Springer-Verlag; 1979.
30. McManus MJ, Welsch CW. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer 1984;54:1920-7.
31. Sutherland RL, Prall OW, Watts CK, Musgrove EA. Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 1998;3:63-72.
32. Kip1. Mol Endocrinol 1997;11:1593-607.
33. Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 1997;11:54-66.
34. Hissom JR, Moore MR. Progestin effects on growth in the human breast cancer cell line T-47D - possible therapeutic implications. Biochem Biophys Res Commun 1987;145:706-11.
35. Musgrove EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032-43.
36. James VHT, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 1987;50:269-79.
37. Blankenstein MA, Van DV, Maitimu-Smeele I, Donker GH, de Jong PC, Daroszewski J, et al. Intratumoral levels of estrogens in breast cancer. J Steroid Biochem Mol Biol 1999;69:293-7.
38. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993;77:1622-8.
39. Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 1991;39:783-90.
40. Murray R. Role of anti-aromatase agents in postmenopansal advanced breast cancer. Cancer Chemother Pharmacol 2001;48:259-65.
41. Iqbal S, Miller WR. New drugs in breast cancer. Exp Opin Pharmacother 2001;2:975-85.
42. Chetrite GS, Pasqualini JR. The selective estrogen enzyme modulator (SEEM) in breast cancer. J Steroid Biochem Mol Biol 2001;76:95-104.
43. Andersson S, Moghrabi N. Physiology and molecular genetics of 17-hydroxysteroid dehydrogenases. Steroids 1997;62:143-7.
44. Pollow K, Boquoi E, Baumann J, Schmidt-Gollwitzer M, Pollow B. Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol 1977;6:333-48.
45. Nguyen B-L, Chetrite G, Pasqualini JR. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells: effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020). Breast Cancer Res Treat 1995;34:139-46.
46. Malet C, Vacca A, Kuttenn F, Mauvais-Jarvis P. 17-Estradiol dehydrogenase (E2DH) activity in T47D cells. J Steroid Biochem Mol Biol 1991;39:769-75.
47. Fournier S, Brihmat F, Durand JC, Sterkers N, Martin PM, Kuttenn F, et al. Estradiol 17-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency. Cancer Res 1985;45:2895-9.
48. Pasqualini JR, Chetrite G, Nguyen B-L, Maloche C, Delalonde L, Talbi M, et al. Estrone sulfate-sulfatase and 17-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 1995;53:407-12.
49. Chetrite G, Paris J, Botella J, Pasqualini JR. Effect of nomegestrol acetate on estrone-sulfatase and 17-hydroxysteroid dehydrogenase activities in human breast cancer cells. J Steroid Biochem Mol Biol 1996;58:525-31.
50. Chetrite GS, Ebert C, Wright F, Philippe J-C, Pasqualini JR. Effect of Medrogestone on 17-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. J Steroid Biochem Mol Biol 1999;68:51-6.
51. Adams EF, Coldham NG, James VHT. Steroidal regulation of oestradiol-17 dehydrogenase activity of the human breast cancer cell line MCF-7. J Endocrinol 1988;118:149-54.
52. Coldham NG, James VHT. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 beta-hydroxysteroid dehydrogenase activity. Int J Cancer 1990;45:174-8.
53. Miller WR, Mullen P. Factors influencing aromatase activity in the breast. J Steroid Biochem Mol Biol 1993;44:597-604.
54. Perel E, Daniilescu D, Kharlip L, Blackstein M, Killinger DW. Steroid modulation of aromatase activity in human cultured breast carcinoma cells. J Steroid Biochem 1988;29:393-9.
55. Chetrite GS, Ebert C, Wright F, Philippe A-C, Pasqualini JR. Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. J Steroid Biochem Mol Biol 1999;70:39-45.
56. Chetrite G, Le Nestour E, Pasqualini JR. Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines: effect of the progestin, promegestone (R5020). J Steroid Biochem Mol Biol 1998;66:295-302.
57. Bush TL, Whiteman M, Flaws J. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508.
58. Campagnoli C, Biglia N, Cantamessa C, Lesca L, Sismondi P. HRT and breast cancer risk: a clue for interpreting the available data. Maturitas 1999;33:185-90.
59. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23.
60. Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999;4:191-210.
61. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59.
62. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-43.
63. Ng E-H, Gao F, Ji C-Y, Ho G-H, Soo K-C. Risk factors for breast carcinoma in Singaporean Chinese women: the role of central obesity. Cancer 1997;80:725-31.
64. Magnusson C, Baron JA, Correia N, Bergström R, Adami H-O, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44.
65. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64.
66. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832-8.
67. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, et al. Estrogen replacement therapy and the risk of breast cancer: results from the Case-Control Surveillance Study. Am J Epidemiol 1991;134:1375-85.
68. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol 1991;134:1386-95.
69. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992;3:475-9.
70. La Vecchia C, Negri E, Franceschi S, Favero A, Nanni O, Filiberti R, et al. Hormone replacement treatment and breast cancer risk: cooperative Italian study. Br J Cancer 1995;72:244-8.
71. Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60.
72. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
73. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788-95.
74. Moorman PG, Kuwabara H, Millikan RC, Newman B. Menopausal hormones and breast cancer in a biracial population. Am J Public Health 2000;90:966-71.
75. Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands Cohort Study. Cancer Causes Control 1995;6:416-24.
76. Levi F, Lucchini F, Pasche C, La Vecchia C. Oral contraceptives, menopausal hormone replacement therapy and breast cancer risk. Eur J Cancer Prev 1996;5:259-66.
77. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997;72:758-61.
78. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson K, Kushi LH, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973-80.
79. Brinton LA, Brogan DR, Coates RJ, Swanson CA, Potischman N, Stanford JL. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998;5:145-51.
80. Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998;51:1277-83.
81. Lando JF, Heck KE, Brett KM. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 1999;17:176-80.
82. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74-9.
83. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
84. Dupont WD, Page DL, Parl FF, Plummer WD Jr, Schuyler PA, Kasami M, et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999;85:1277-83.
85. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994;70:270-7.
86. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357-63.
87. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortally. J Natl Cancer Inst 2001;93:754-61.
88. Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995;2:67-72.
89. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137-42.
90. Eden JA, Durna EM, Wren BG, Heller G, Leader LR. HRT after breast cancer: the latest results from the Royal Hospital for Women breast cancer study [abstract]. Proceedings of the 5th Australasian Menopause Society Congress, Melbourne, Australia, 23-27 Oct, 2001. Melbourne: The Society; 2001.
91. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, et al. Estrogen replacement therapy in breast cancer survivors. JAMA 1994;272:540-5.
92. Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002;177:347-51.
93. Cuzick J. Is hormone replacement therapy safe for breast cancer patients? J Natl Cancer Inst 2001;93:733-4.
94. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;4:262-9.
95. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
96. McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol 1994;163:311-5.
97. Lundström E, Wilczek B, von Palffy Z, Söderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52.
98. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-7.
99. Sterns EE, Zee B. Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable? Breast Cancer Res Treat 2000;59:125-32.
100. Erel CT, Seyisoglu H, Senturk ML, Akman C, Ersavasti G, Benian A, et al. Mammographic changes in women on hormonal replacement therapy. Maturitas 1996;25:51-7.
101. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990;174:487-90.
102. Ozdemir A, Konus O, Nas T, Erba G, Cosar S, Isik S. Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynaecol Obstet 1999;67:23-32.
103. Colacurci N, Fornaro F, de Franciscis P, Mele D, Palermo M, del Vecchio W. Effects of a short-term suspension of hormone replacement therapy on mammographic density. Fertil Steril 2001;76:451-5.
104. Sendag F, Cosan Terek M, Ozsener S, Oztekin K, Bilgin O, Bilgen I, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445-50.
105. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
106. Harvey JA, Pinkerton JV, Herman CR. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 1997;89:1623-5.
107. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
108. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City). Cancer Causes Control 1995;6:431-8.
109. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
110. Speroff L. Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to an epidemiologic report. Contemp OB/GYN 2000;103-22.
111. Stomper PC, D'Souza DJ, DiNitto PA, Arredondo MA. Analysis of parenchymal density on mammograms in 1353 women 25-79 years old. AJR Am J Roentgenol 1996;167:1261-5.
112. Shoupe D. HRT dosing regimens: continuous versus cyclic - Pros and cons. Int J Fertil 2001;45:7-15.
113. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
114. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8.
115. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
116. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449-57.
117. Bergkvist L, Adami H-O, Persson I, Bergström R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221-8.
118. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11-7.
119. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32.
120. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999;91:264-70.
121. Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, et al. Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol 1999;17:1680-8.
122. Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999;80:1453-8.
123. DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol 2000;23:541-5.
124. LaCroix AZ, Burke W. Breast cancer and hormone replacement therapy. Lancet 1997;350:1042-3.
125. Gajdos C, Tartter PI, Babinszki A. Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol 2000;95:513-8.
126. Bonnier P, Bessenay F, Sasco AJ, Beedassy B, Lejeune C, Romain S, et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998;79:278-82.
127. Salmon RJ, Ansquer Y, Asselain B, Languille O, Lesec G, Remvikos Y. Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause. Oncol Rep 1999;6:699-703.
128. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998;16:3115-20.
129. O'Connor IF, Shembekar MV, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 1998;51:935-8.
130. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996;38:325-34.
131. Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994;178:167-70.
132. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ 1996;312:1646-7.
133. Bilimoria MM, Winchester DJ, Sener SF, Motykie G, Sehgal UL, Winchester DP. Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Ann Surg Oncol 1999;6:200-7.
134. Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992;80:400-4.
135. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA 1999;281:1528-30.